|
|
 |
|
Viewing report
|
|
|
|
Pipeline and Commercial Insight: Moderate to Severe Chronic Nociceptive Pain - Anti-abuse opioids set to prosper
Datamonitor, Aug 2010, Pages: 223
Introduction
The moderate to severe chronic nociceptive pain market has boomed in the years since the removal of generic extended-release oxycodone from the US, growing in value to eclipse $10 billion. However, this reprieve will be short-lived with the pipeline and recently-launched drugs unable to fill the void left by generic erosion of OxyContin (controlled-release oxycodone, Purdue).
Scope
-Analysis of patient segmentation, epidemiology, current treatment approaches, the patient acquisition process and clinical unmet needs
-Breakdown of historic (200509) and future (201019) prescription sales across the seven major markets (US, Japan, France, Germany, Italy, Spain, UK)
-Review of key pipeline trends, issues in clinical trial design and the implications of Risk Evaluation and Mitigation Strategies required by the FDA
-Commercial and clinical assessment of key late-stage pipeline drugs, with key opinion leader comment and region-specific sales forecasts to 2019
Highlights
Aided by continued growth of OxyContin and the launch of opioids incorporating anti-abuse technologies, the market is set to peak at $11.7 billion in 2012. Thereafter, the market will contract to reach $10.5 billion in 2019, when the effect of patent expiries on key brands offsets sales growth of new drugs.
Nucynta ER is the most clinically and commercially attractive pipeline drug, eclipsing the gold standard OxyContin. Backed by Johnson & Johnson, Nucynta ER is forecast to make a significant impact upon the market. Remoxy (extended-release oxycodone, King) and EG-P066 (extended-release morphine) are also both expected to feature as leading brands.
Expectations of the novel anti-NGF class have been dampened following revelations of the osteoarthritis-worsening side effects of tanezumab (RN624, Pfizer). Datamonitor predicts that tanezumab, an NGF monoclonal antibody, will reach the market; however, as a last line therapy in severe cancer pain.
Reasons to Purchase
-Quantify the current and future size of the moderate to severe chronic nociceptive pain market
-Understand the country-specific impact of key events in the moderate to severe chronic nociceptive pain market during the forecast period 2010-19
-Identify potential licensing opportunities based on product portfolios and anticipated market needs
Customers who bought this item also bought
Commercial Insight: Opioids in Australia
Moderate to Severe Chronic Nociceptive Pain Market Forecast
Pipeline Insight: Moderate-to-Severe Acute Pain - Positive outlook for opioid-sparing analgesics
Pipeline and Commercial Insight: Neuropathic Pain - Pipeline setbacks prolong Pfizer's supremacy
Pipeline Insight: Epilepsy - Past successes hard to emulate in highly genericized market
Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitors bring added benefits to diabetes therapy.
Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers
Pipeline Insight: Inflammatory Bowel Disease - Varied drug targets to broaden future therapy options
Pipeline and Commercial Insight: Migraine - Challenges ahead for first-in-class developments
Stakeholder Opinions: Targeting Nerve Growth Factor for Pain Therapy - Groundbreaking class to breathe new life into saturated market
|
|
|
|
